Foluso Olabisi Ademuyiwa MD

Oncology•Saint Louis, MO

Breast Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Washington University in St. Louis School of Medicine

Join to View Full Profile

4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 800-647-2098

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine/Pediatrics, 2002 - 2006
University of IbadanClass of 1999

Awards, Honors, & Recognition

Best Doctor in St Louis 2015-2016

Clinical Trials

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04
Terminated
Not Applicable
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer Start of enrollment: 2013 Jun 01
Completed
Phase 1
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Start of enrollment: 2015 Jan 07
Active, not recruiting
Phase 1
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Start of enrollment: 2017 Jun 30
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer.
Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher, Rama Suresh, Lindsay L Peterson
Clinical Cancer Research. 2025-03-21
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer.
Emily L Podany, Lorenzo Foffano, Lorenzo Gerratana, Arielle J Medford, Katherine Clifton
JAMA Network Open. 2025-02-03
2 citations
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.
Michael D Iglesia, Reyka G Jayasinghe, Siqi Chen, Nadezhda V Terekhanova, John M Herndon
Nature Cancer. 2024-11-01

Press Mentions

Interventions Needed to Support Mammography Attendance Among Black WomenApril 21st, 2021
Study Aims to Find Clues to Breast Cancer Outcomes in African-American WomenJuly 14th, 2016

Foluso Olabisi Ademuyiwa MD

Dr. Ademuyiwa is on Doximity

Education & Training

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.